Half of the patients who completed the study chose to continue treatment with escitalopram rather than taper down the dose at 32 weeks .
We examine patient characteristics , 12-month treatment success ( ie , retention or taper after 6 months ) , and predictors of successful outcomes .
Appropriate examinations should be performed regularly in order to decide whether to taper or stop when damage is still mild , preclinical , or reversible .
